P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients

L. Scarallo, S. Pochesci, L. Fioretti, M. Paci, S. Renzo, S. Naldini, L. Lacitignola, J. Barp, E. Banci, A. De Blasi, P. Lionetti
{"title":"P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients","authors":"L. Scarallo, S. Pochesci, L. Fioretti, M. Paci, S. Renzo, S. Naldini, L. Lacitignola, J. Barp, E. Banci, A. De Blasi, P. Lionetti","doi":"10.1093/ecco-jcc/jjad212.1049","DOIUrl":null,"url":null,"abstract":"\n \n \n Despite the accumulating body of evidence of the efficacy and tolerability of Crohn’s disease exclusion diet (CDED) combined with partial enteral nutrition (PEN), there is still a paucity data regarding its use in combination with other medical treatments. We aimed at assessing its efficacy in re-inducing remission in pediatric CD patients experiencing disease relapse while on other maintenance therapies.\n \n \n \n This was a single-center, retrospective, observational study conducted at an Italian national referral pediatric IBD center. Incident patients who received CDED coupled with PEN in the setting of the loss of response to other maintenance therapies from January 1st, 2020 to June 30th 2023 were included. Clinical remission at the end of each phase was defined by a weighted Pediatric Crohn’s Disease Activity Index (wPCDAI) below 12.5. Biochemical remission was defined by a c-reactive protein (CRP) lower than 0.5 mg/dL. A FC lower than 150 mg/kg was used as a surrogate of mucosal improvement (MI).\n \n \n \n 25 patients (52% males) met inclusion criteria and were included in the analysis. Median disease duration at CDED+PEN initiation was 31 months (Q1-Q3: 8.4-13.8). The most frequent disease location was ileocolonic (64%), 3 (12%) patients had isolated colonic involvement. 9 (36%) patients had stricturing/penetrating phenotype. 16 patients (68%) were being treated with an anti-TNF-alpha agent, whereas 5 (20%) patients were receiving ustekinumab (Table 1). wPCDAI, CRP and FC significantly decreased after the firs 8 weeks of treatment (22.5 vs 2.5, 1 vs 0.2, 640 vs 360, p<0.001, p=0.019 and p=0.007, respectively). At the end of phase I, 19/25 (76%) of the patients achieved clinical remission, 15 (60%) patients had CRP levels within normal range and 7 (28%) of them had normalized FC. 18/25 patients (72%) had received Exclusive Enteral Nutrition (EEN) for the induction of remission at diagnosis. Patients who achieved clinical remission with the EEN course (i.e.: a wPCDAI of < 12.5 after a complete course of EEN) were more likely to achieve clinical remission when receiving CDED + PEN (11/13 vs 1/5, p=0.022).\n \n \n \n CDED coupled with PEN is a valid treatment strategy in the setting of secondary loss of response to maintenance treatments in children with CD. A previous successful course of EEN was associated with higher rates of clinical remission at the end of phase I, thereby possibly identifying a subset of “nutritional responder” patients.\n \n","PeriodicalId":15453,"journal":{"name":"Journal of Crohn's and Colitis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohn's and Colitis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjad212.1049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the accumulating body of evidence of the efficacy and tolerability of Crohn’s disease exclusion diet (CDED) combined with partial enteral nutrition (PEN), there is still a paucity data regarding its use in combination with other medical treatments. We aimed at assessing its efficacy in re-inducing remission in pediatric CD patients experiencing disease relapse while on other maintenance therapies. This was a single-center, retrospective, observational study conducted at an Italian national referral pediatric IBD center. Incident patients who received CDED coupled with PEN in the setting of the loss of response to other maintenance therapies from January 1st, 2020 to June 30th 2023 were included. Clinical remission at the end of each phase was defined by a weighted Pediatric Crohn’s Disease Activity Index (wPCDAI) below 12.5. Biochemical remission was defined by a c-reactive protein (CRP) lower than 0.5 mg/dL. A FC lower than 150 mg/kg was used as a surrogate of mucosal improvement (MI). 25 patients (52% males) met inclusion criteria and were included in the analysis. Median disease duration at CDED+PEN initiation was 31 months (Q1-Q3: 8.4-13.8). The most frequent disease location was ileocolonic (64%), 3 (12%) patients had isolated colonic involvement. 9 (36%) patients had stricturing/penetrating phenotype. 16 patients (68%) were being treated with an anti-TNF-alpha agent, whereas 5 (20%) patients were receiving ustekinumab (Table 1). wPCDAI, CRP and FC significantly decreased after the firs 8 weeks of treatment (22.5 vs 2.5, 1 vs 0.2, 640 vs 360, p<0.001, p=0.019 and p=0.007, respectively). At the end of phase I, 19/25 (76%) of the patients achieved clinical remission, 15 (60%) patients had CRP levels within normal range and 7 (28%) of them had normalized FC. 18/25 patients (72%) had received Exclusive Enteral Nutrition (EEN) for the induction of remission at diagnosis. Patients who achieved clinical remission with the EEN course (i.e.: a wPCDAI of < 12.5 after a complete course of EEN) were more likely to achieve clinical remission when receiving CDED + PEN (11/13 vs 1/5, p=0.022). CDED coupled with PEN is a valid treatment strategy in the setting of secondary loss of response to maintenance treatments in children with CD. A previous successful course of EEN was associated with higher rates of clinical remission at the end of phase I, thereby possibly identifying a subset of “nutritional responder” patients.
P919 克罗恩病排除饮食作为难治性儿科患者的附加疗法
尽管越来越多的证据表明克罗恩病排除饮食(CDED)与部分肠内营养(PEN)相结合具有疗效和耐受性,但有关其与其他药物治疗联合使用的数据仍然很少。我们的目的是评估 CDED 对正在接受其他维持性治疗但病情复发的儿童 CD 患者重新获得缓解的疗效。 这是一项在意大利国家儿科 IBD 转诊中心进行的单中心、回顾性、观察性研究。研究对象包括在 2020 年 1 月 1 日至 2023 年 6 月 30 日期间接受 CDED 和 PEN 治疗,但对其他维持疗法无效的患者。每个阶段结束时的临床缓解定义为加权小儿克罗恩病活动指数(wPCDAI)低于 12.5。生化缓解的定义是 c 反应蛋白(CRP)低于 0.5 毫克/分升。FC 低于 150 毫克/千克被用作粘膜改善(MI)的替代指标。 25名患者(52%为男性)符合纳入标准并被纳入分析。CDED+PEN 开始治疗时的中位病程为 31 个月(Q1-Q3:8.4-13.8)。最常见的疾病部位是回结肠(64%),3 名(12%)患者有孤立的结肠受累。9名患者(36%)有狭窄/穿透表型。16名患者(68%)正在接受抗肿瘤坏死因子-α药物治疗,5名患者(20%)正在接受乌斯特库单抗治疗(表 1)。治疗最初 8 周后,wPCDAI、CRP 和 FC 显著下降(分别为 22.5 vs 2.5、1 vs 0.2、640 vs 360,p<0.001、p=0.019 和 p=0.007)。第一阶段结束时,19/25(76%)名患者实现了临床缓解,15(60%)名患者的 CRP 水平在正常范围内,其中 7(28%)名患者的 FC 恢复正常。18/25(72%)名患者在确诊时接受了肠外营养(EEN)以诱导病情缓解。接受肠内营养治疗后获得临床缓解的患者(即:在接受一个完整疗程的肠内营养治疗后,wPCDAI<12.5)更有可能在接受CDED+PEN治疗后获得临床缓解(11/13 vs 1/5,P=0.022)。 CDED+PEN是CD患儿对维持治疗继发失效时的一种有效治疗策略。在第一阶段结束时,曾成功接受过EEN治疗的患者临床缓解率较高,因此可能会确定 "营养应答 "患者的子集。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信